This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a multi-centre randomised controlled trial. The duration of follow-up was one year. Eleven patients were lost to follow-up. The patients were randomly assigned to either low-dose amiodarone (intervention) or sotalol or propafenone (control) . No further details of the randomisation were reported.
Analysis of effectiveness
The basis of the analysis was treatment completers only. The primary health outcomes used were whether patients had been hospitalised and if they had undergone a catheter ablation, pacemaker implantation or cardioversion. A significantly larger proportion of participants in the control group (sotalol or propafenone) had left ventricular hypertrophy, otherwise the two groups were similar.
Effectiveness results
The proportion of patients with a cardioversion was 32% in the amiodarone group compared with 54% in the control group, (p<0.0001).
The proportion of patients with a pacemaker was 2% in the amiodarone group compared with 5.5% in the control group, (p=0.07).
The proportion of patients with a catheter ablation was 1.5% in both groups, (p=1).
The average number of days in the hospital for AF was 0.47 in the amiodarone group compared with 0.97 in the control group, (p=0.01).
The average number of days in the intensive care unit (ICU) for AF was 0.07 in the amiodarone group compared with 0.11 in the control group, (p=0.48).
The average number of hospital visits was 0.58 in the amiodarone group compared with 0.59 in the control group, (p=0.91).
The average number of days in hospital was 4.11 in the amiodarone group compared with 3.79 in the control group, (p=0.76).
The average number of days in the ICU was 0.40 in the amiodarone group compared with 0.48 in the control group, (p=0.68).
The average number of emergency room visits was 1.20 in the amiodarone group compared with 1.24 in the control group, (p=0.89).
Clinical conclusions
Patients on amiodarone used significantly fewer resources for problems directly related to AF. For hospitalisations for all diagnoses there was no difference between the groups.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary measure of benefit was used. In effect, a costconsequences analysis was conducted.
Direct costs
Discounting was not relevant since the costs were incurred during one year. The costs of hospitalisation were estimated using the Ontario Case Cost Project and, when data were not available from this source, they were taken from the Montreal Heart Institute. The costs were calculated using the most recent data available (1995/96) . Resource use and the unit costs were not reported separately.
